pre-IPO PHARMA

COMPANY OVERVIEW

Rivus Pharmaceuticals, Inc., is dedicated to transforming the treatment of cardio-metabolic disease. Rivus' first-in-class, small molecule therapy, HU6, is a controlled metabolic accelerator (CMA) that addresses the underlying cause of cardio-metabolic disease by harnessing the body's natural processes to improve cellular metabolism. Rivus' therapy presents a tremendous opportunity to empower patients on their journey to better health when facing a broad range of cardio-metabolic conditions, including type 2 diabetes, hypertension, non-alcoholic steatohepatitis (NASH), dyslipidemia and obesity.


LOCATION

  • Charlottesville, VA 22903, VA, USA

  • THERAPEUTIC AREAS

  • Cardiovascular Disease
  • Metabolic Disorders

  • WEBSITE

    https://www.rivuspharma.com/


    CAREER WEBSITE

    https://www.rivuspharma.com/


    SOCIAL MEDIA


    INVESTORS

    longitude-capital medicxi rxcapital


    PRESS RELEASES


    Jun 29, 2023

    Rivus Pharmaceuticals Announces Leadership Transition, Appointment of Jayson Dallas, M.D., as CEO


    Nov 4, 2022

    Rivus Pharmaceuticals to Present Results from a Phase 2a Trial Evaluating its Controlled Metabolic Accelerator, HU6, at the American Association for the Study of Liver Diseases (AASLD)2022 Meeting


    Sep 22, 2022

    Rivus Pharmaceuticals Closes $132 Million Series B Financing to Advance HU6 for the Treatment of Obesity and Cardio-Metabolic Disorders


    Feb 9, 2022

    Rivus Pharmaceuticals Announces Positive Data from Phase 2a Clinical Trial of Lead Candidate HU6, Demonstrating Fat Reduction and Weight Loss in High BMI Participants


    Nov 1, 2021

    Rivus Pharmaceuticals Announces Positive Results from Phase 1 Trial of Lead Candidate HU6, Demonstrating Safety, Efficacy in Key Targets for Multiple Cardio-Metabolic Diseases


    For More Press Releases


    Google Analytics Alternative